Head Multiple Myeloma, US Medical Affairs at Janssen
Janssen Scientific Affairs, LLC, Horsham, PA, USA
Thomas Lin is Head of Multiple Myeloma in US Medical Affairs at Janssen Oncology, where he oversees US medical affairs activities for daratumumab, teclistamab and talquetamab. He also previously oversaw US medical affairs activities for ciltacabtagene autoleucel and ibrutinib. Prior to joining Janssen as the US Medical Affairs Therapeutic Area Lead for Hematologic Malignancies in 2014, he spent 5 years in clinical development in Oncology R&D at GlaxoSmithKline. At GSK, he was the Project Physician Leader (PPL) accountable for the clinical development programs for the anti-CD20 monoclonal antibody ofatumumab and the anti-CD20 antibody I-131 tositumomab (Bexxar). Prior to joining GSK in 2009, he was Associate Professor of Internal Medicine in the Division of Hematology and Oncology at The Ohio State University, where his research and clinical focus was phase I/II drug development in CLL and other lymphoid malignancies. He was an attending physician in the Hematology clinic and Blood and Marrow Transplant service at Ohio State. He received his MD and PhD degrees from Yale University and completed a residency in internal medicine at Brigham and Women’s Hospital and fellowships in adult oncology and hematology at Dana-Farber Cancer Institute. He is board certified in Hematology and Medical Oncology. He has authored or coauthored more than 250 publications and abstracts.